Whippany, NJ – May 1, 2026 – Halo Pharma (the “Company”), a leading CDMO partner to the pharmaceutical industry and previous division of Noramco Group, is now operating as a standalone business following Siegfried’s acquisition of Noramco Group’s small molecule API assets.

Owned and supported by funds advised by SK Capital, the Company serves as a dedicated, specialized platform focused on developing and manufacturing products for its pharmaceutical customers. Halo Pharma has invested heavily to support its active expansion into sterile product development and fill/finish services to support growing customer demand.

“Building on decades of supporting pharmaceutical and healthcare clients, Halo Pharma is entering an exciting new phase as an independent CDMO,” said Lee Karras, CEO of Halo Pharma. “We are focused on expanding our capabilities to meet evolving customer needs, including the launch of sterile injectable manufacturing at our Whippany, New Jersey facility, which we expect to bring online in the second half of this year.”

The Company’s expansion into sterile injectables is supported by a more than $30 million investment into its Whippany facility, establishing high-speed filling capabilities for ready-to-use syringes, cartridges, and vials. The new line will support batch sizes ranging from 5,000 to 250,000 units, with an annual production capacity exceeding 50 million units.

Sterile injectables represents one of the fastest-growing and most capacity-constrained segments of the pharmaceutical market. These expanded capabilities will provide customers with a reliable, North American-based manufacturing solution for both clinical and commercial supply. Reflecting this demand, Halo Pharma recently entered into a strategic partnership with Apotex Corp., which will provide Apotex access to a portion of the company’s overall sterile injectable filling capacity, while preserving ample availability for additional customers.

As a standalone organization, Halo Pharma is strategically-focused and well-positioned to serve the global pharmaceutical market. The expanded capabilities at its Whippany, New Jersey site will serve as a key hub for U.S.-based development and production, with capabilities now spanning solid dose, oral liquid, and sterile manufacturing, supported by enhanced tech transfer capabilities designed to accelerate progression into GMP manufacturing. Complementing this, the Company’s Mirabel, Quebec facility provides solid dose, semi-solid, bulk powder, oral liquid, and suppository development and manufacturing, supported by the same integrated development and transfer capabilities. Together, the two sites provide the scale, flexibility, and quality systems needed to support both domestic and international programs.

For more information about Halo Pharma, visit https://halopharma.com.

About Halo Pharma
Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise, as well as a wide spectrum of manufacturing services, from its locations in Whippany, New Jersey, USA, and Montreal, Quebec, Canada, to its international client base. Halo Pharma offers fully integrated capabilities across a variety of dosage forms, including solid, semi-solid, and oral liquid, and is expanding to include sterile vial, prefilled syringe, and cartridge formats. The company is registered to work with any of these dosages in the CI–CV DEA designations. Halo Pharma’s capabilities in tech transfer, process and product development, production, scale-up/validation, and analytical method development allow it to partner with clients from development through commercialization—or at any point along the way. For more information, please contact services@halopharma.com.

About SK Capital
SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, material sciences, and specialty ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital manages funds with over $8.5 billion in aggregate commitments. For more information, please visit www.skcapitalpartners.com.

Media Contact
Resource Advantage
Dan Green
dgreen@resourceadvantage.com

Company Contact
Halo Pharma & Woodstock Sterile Solutions
Stacy London
Stacy.london@wssterile.com